% | $
Quotes you view appear here for quick access.

VIVUS Inc. Message Board

  • pressman_john pressman_john May 25, 2012 6:30 PM Flag


    Seeking Alpha May 25,2012
    By: Scott Matusow
    It appears more likely than not Arena will not be required by the FDA to engage in a Risk Evaluation and Mitigation Strategy (REM) as Vivus (VVUS) was required to do when its weight loss drug Qnexa was also recently recommended for approval by an advisory panel.
    It is my opinion that approval of Lorcaserin is a given at this point. Again, it does not seem to me that a REM will be required by the FDA, possibly making Lorcaserin the first doctor proscribed weight loss drug to hit the market since 1999. Arena to me is looking less like a speculative investment, and more like a long term winner. Keep a close eye on this one after a successful secondary offering was completed at $5.50 a share. This might be a good time to buy Arena stock for the long haul in my opinion.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.16+0.04(+3.57%)Oct 25 4:00 PMEDT